Sentence examples for more complex antibody from inspiring English sources

The ability to express antibody heavy and light chains from separate but compatible high copy plasmids should allow new opportunities in antibody engineering, such as rapid chain shuffling and generation of more complex antibody libraries.

In contrast, the multiple infections experienced with increasing age in high malaria transmission areas may generate a more complex antibody repertoire, including a subset of antibodies that interfere with or impair functional inhibitory activity.

IgG-like bivalent scFv-Fc antibodies perform well in most immunoassays, but production of more complex antibody formats like scFv-Fc requires eukaryotic or even mammalian expression systems to achieve high yields of functional protein and to reduce the efforts during downstream processing [ 24].

This procedure is more complex than the antibody biotinylation of the three-step method, which requires a simple chemical reaction followed by buffer exchange and which is therefore more suitable to industrial development.

Human monoclonal antibodies are a powerful tool with increasingly successful exploitations and the single chain fragment variable format can be considered the building block for the implementation of more complex and effective antibody-based constructs.

The IgG backbone is also used to design more potent but also more complex biopharmaceuticals such as antibody-drug conjugates, bispecific antibodies, Fc-fusion proteins, and antibody mixtures to name a few.

Although the immobilized p53 antigens reacted with a commercial p53 mAbs in a dose response manner, human serum is far more complex than the commercial antibody.

Pharmacokinetics and pharmacodynamics of monoclonal antibodies are more complex compared to small-molecule drugs.

Moreover, efficient secretory production of more complex IgG-like scFv-Fc antibodies facilitates downstream processing and increases the compatibility to standard immunoassays and other applications compared to small recombinant antibody fragments.

When radiolabelled antibodies bind to blood, bone and bone marrow components or when the radionuclide accumulates in bone or bone marrow upon metabolisation of the radionuclide antibody complex, calculation of the red marrow dose is more complex than when using radiolabelled antibodies that lack these characteristics [ 66, 67].

The front can in fact be a diffusing molecule which does not interact with white matter cells, or a molecule involved in more complex interactions with macrophages, like an antibody.